Produkty 1469876-18-3

CAS 1469876-18-3 występuje w naszej ofercie pod nazwami: Labetuzumab govitecan, Labetuzumab govitecan, 90%, 90%, Labetuzumab govitecan, 98.66%. Oferty producentów: GLPBio, Chemat, MedChemExpress. Dostępne opakowania: 1mg, 5mg, 5 mg, 1 mg.

Labetuzumab govitecan
GLPBio
  • opakowanie: 1mg
  • Warianty: 1
od 3700,21
Zobacz produkt
Labetuzumab govitecan, 90%, 90%
Chemat
  • opakowanie: 1mg, 5mg
  • Warianty: 2
od 2584,40
Zobacz produkt
Labetuzumab govitecan, 98.66%
MedChemExpress
  • opakowanie: 5 mg, 1 mg
  • Warianty: 2
od 3863,06
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(2R)-2-amino-3-[1-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[2-[2-[[(2S)-5-amino-1-[4-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxycarbonyloxymethyl]anilino]-1-oxopentan-2-yl]amino]-2-oxoethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methylcarbamoyl]cyclohexyl]methyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid (CAS 1469876-18-3) to związek chemiczny o wzorze sumarycznym C75H102N12O24S i masie molowej 1587.7 g/mol. Nazwa systematyczna IUPAC: (2R)-2-amino-3-[1-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[2-[2-[[(2S)-5-amino-1-[4-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxycarbonyloxymethyl]anilino]-1-oxopentan-2-yl]amino]-2-oxoethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methylcarbamoyl]cyclohexyl]methyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid. InChIKey: CBNAAKBWBABMBY-LQCKLLCCSA-N.

Dane identyfikacyjne
Wzór sumarycznyC75H102N12O24S
Masa molowa1587.7 g/mol
Nazwa IUPAC(2R)-2-amino-3-[1-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[2-[2-[[(2S)-5-amino-1-[4-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxycarbonyloxymethyl]anilino]-1-oxopentan-2-yl]amino]-2-oxoethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methylcarbamoyl]cyclohexyl]methyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
InChIKeyCBNAAKBWBABMBY-LQCKLLCCSA-N
SMILESCCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SC[C@@H](C(=O)O)N)C2=NC9=C1C=C(C=C9)O

Dane obliczone przez PubChem (NCBI)

Synonimy: Labetuzumab govitecan, hMN14-SN38, Anti-ceacam5-sn 38, labetuzumabum govitecanum, Antibody-Drug Conjugate IMMU-130, Labetuzumab-SN-38 Immunoconjugate IMMU-130, Labetuzumab-SN38, Labetuzumab govitecan [USAN], labetuzumab-govitecan, orb1987070